Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Brian Elliott,2 Andrew Briggs3 1Department of Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA; 3William R. Lindsay Chair...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2018-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|